Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Latigo Biotherapeutics, Inc. Common Stock

LTGO

Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

Last trade $13.34
Day change +$0.74 (+5.87%)
Day range $12.33 – $13.54
Volume 127,520
Market cap $835M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for LTGO.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for LTGO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026
Revenue$0
Cost of revenue$0
Gross profit$0
Selling, general and administrative$5.43M
Research and development$17.5M
Total operating expenses$22.93M
Operating income-$22.93M
Interest expense-$699K
Income before taxes-$20.95M
Income taxes$0
Net income-$20.95M
Net income attributable to common shareholders-$20.95M
EBITDA-$22.88M
Basic earnings per share-$0.55
Diluted earnings per share-$0.55

Recent news

Company coverage with links to the original publishers.

Publication times in UTC

No recent company news found.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.